SCHEMBL10244320

SCHEMBL10244320

CNC(=O)NCC(O)CNc1ccccc1OC

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
PPARG P37231 1/20 0.43
ADRB2 P07550 1/20 0.42
POLB P06746 1/20 0.42
ANPEP P15144 1/20 0.41
LPAR1 Q92633 1/20 0.41
GAA P10253 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10282644 0.83 MAPT (0.60) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL10245164 0.77 MAPT (0.58) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL334451 0.77 MAPT (0.60) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL6327499 0.73 MAPT (0.56) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL13923626 0.73 SMN1; SMN2 (0.68) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL13411706 0.72 HSD17B10 (0.36) MAPTKMT2AADRB2MTNR1A
SCHEMBL18236653 0.71 CHRM2 (0.53) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL7615058 0.70 CHRM2 (0.51) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL5352418 0.69 MAPT (0.48) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL29147807 0.69 MAPT (0.48) MAPTMEN1KMT2ATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MAPT 4302/4885MEN1 2456/4885KMT2A 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.